Linnaeus Therapeutics
Development stage biotech company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | $1.6m | Late VC | |
| Total Funding | 000k | ||
Related Content
Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company, was founded in 2018 by Dr. Todd Ridky, a physician-scientist at the University of Pennsylvania, and his then-graduate student, Christopher Natale, who now serves as the company's Director of Research. The company is a spinout from the University of Pennsylvania and is focused on the development and commercialization of novel small-molecule oncology therapeutics.
The company's lead candidate, LNS8801, is a small molecule that has shown promise in preclinical studies for its ability to target a protein that is believed to play a role in the development of cancer. Linnaeus is currently conducting a Phase 1 clinical trial of LNS8801 in patients with advanced cancers.
The company's business model is to develop and commercialize its own proprietary drugs. Linnaeus has raised over $1.6 million in funding from investors.
Keywords: biopharmaceutical, oncology, therapeutics, small-molecule, cancer, clinical-stage, research, development, LNS8801, treatment